Investigator
Hans Gregersen
CALIFORNIA MEDICAL INNOVATIONS INSTITUTE · funded by NIDDK
- Companies
- 2
- Grants
- 4
- Non-dilutive funding
- $2.0M
- First award
- Jun 15, 2021
Resolved onto their grants.
Federal awards on file.
Summed across those awards.
Latest Mar 1, 2023.
Companies from this work
Pre-ticker companies the crosswalk resolved onto a grant filed under this investigator. Momentum shows for the therapeutic areas your seat covers; open a dossier for the full crosswalk.
- CALIFORNIA MEDICAL INNOVATIONS INSTITUTEMomentum in another area
Grant-only
- CALIFORNIA MEDICAL INNOVATIONS INSTITUTEMomentum in another area
Grant-only
Grant record
Federal awards filed under this investigator name, newest first. Each links to the public record where the awarding agency publishes one.
- R01
Fecobionics monitoring and prediction of biofeedback therapy outcome in patients with obstructed defecation.
$370kMar 1, 2023NIDDKCALIFORNIA MEDICAL INNOVATIONS INSTITUTENIH RePORTER · 11060050 (opens the source filing in a new tab)
- R01
Pathophysiology, diagnosis and biofeedback therapy in fecal incontinence using fecobionics
$535kAug 1, 2022NIDDKCALIFORNIA MEDICAL INNOVATIONS INSTITUTENIH RePORTER · 11140302 (opens the source filing in a new tab)
- R01
Pathophysiology, diagnosis and biofeedback therapy in fecal incontinence using fecobionics
$523kAug 1, 2022NIDDKCALIFORNIA MEDICAL INNOVATIONS INSTITUTENIH RePORTER · 11374528 (opens the source filing in a new tab)
- R01
Defecation mechanisms and subtyping of constipation patients with Fecobionics
$544kJun 15, 2021NIDDKCALIFORNIA MEDICAL INNOVATIONS INSTITUTENIH RePORTER · 11164491 (opens the source filing in a new tab)
This page aggregates public U.S. federal grant records filed under one investigator name and the companies Biodatica has resolved onto them. Names are shown as the awarding agency filed them; grant awards are non-dilutive federal funding, not equity or valuation. Distinct people who file under the same name would appear together here. It is informational only and not investment advice. Methodology · Data sources